Multiple mechanisms mediating carbon monoxide inhibition of the voltage-gated K+ channel Kv1.5

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access


It is advisable to refer to the publisher's version if you intend to cite from the work. See Guidance on citing.

To link to this article DOI: http://dx.doi.org/10.1038/cddis.2017.568

Publisher: Nature Publishing Group

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

www.reading.ac.uk/centaur
CentAUR
Central Archive at the University of Reading
Reading's research outputs online
Multiple mechanisms mediating carbon monoxide inhibition of the voltage-gated K^+ channel Kv1.5

Moza M Al-Owais¹, Nishani T Hettiarachchi¹, John P Boyle¹, Jason L Scrugg¹, Jacobo Elies¹,³, Mark L Dallas¹,⁴, Jon D Lippiat², Derek S Steele² and Chris Peers*,¹

The voltage-gated K^+ channel has key roles in the vasculature and in atrial excitability and contributes to apoptosis in various tissues. In this study, we have explored its regulation by carbon monoxide (CO), a product of the cytoprotective heme oxygenase enzymes, and a recognized toxin. CO inhibited recombinant Kv1.5 expressed in HEK293 cells in a concentration-dependent manner that involved multiple signalling pathways. CO inhibition was partially reversed by superoxide dismutase mimetics and by suppression of mitochondrial reactive oxygen species. CO also elevated intracellular nitric oxide (NO) levels. Prevention of NO formation also partially reversed CO inhibition of Kv1.5, as did inhibition of soluble guanylyl cyclase. CO also elevated intracellular peroxynitrite levels, and a peroxynitrite scavenger markedly attenuated the ability of CO to inhibit Kv1.5. CO caused nitrosylation of Kv1.5, an effect that was also observed in C331A and C346A mutant forms of the channel, which had previously been suggested as nitrosylation sites within Kv1.5. Augmentation of Kv1.5 via exposure to hydrogen peroxide was fully reversed by CO. Native Kv1.5 recorded in HL-1 murine atrial cells was also inhibited by CO. Action potentials recorded in HL-1 cells were increased in amplitude and duration by CO, an effect mimicked and occluded by pharmacological inhibition of Kv1.5. Our data indicate that Kv1.5 is a target for modulation by CO in this cell system. This regulation has important implications for diverse cellular functions, including excitability, contractility and apoptosis.

Cell Death and Disease (2017) 8, e3163; doi:10.1038/cddis.2017.568; published online 2 November 2017

Kv1.5 is a rapidly activating, voltage-gated K^+ channel encoded by KCNA5 that inactivates slowly and incompletely.¹ Distribution of Kv1.5 is widespread: it is expressed in various cell types in the central nervous system²,³ and is implicated in certain types of cancers.⁴ Kv1.5 is, however, perhaps best studied in the cardiovascular system. Its expression/activity is associated with increased apoptosis in endothelial and smooth muscle cells.⁵,⁶ In vascular smooth muscle cells (VSMCs) of the pulmonary vasculature, it is of particular importance to hypoxic pulmonary vasoconstriction⁷–⁹ and in the development of pulmonary arterial hypertension (PAH).¹⁰–¹² Indeed, Kv1.5 expression is reduced in PAH patients¹³ and patients with idiopathic PAH possess important single-nucleotide polymorphisms in KCNA5, which encodes Kv1.5.¹⁴,¹⁵ In the systemic circulation, Kv1.5 also contributes to repolarization of the VSMC membrane potential, limiting Ca²⁺ entry and hence vascular tone.¹⁶–¹⁸ A recent study employing Kv1.5⁻/⁻ mice has shown that this channel is essential for balancing coronary blood flow with metabolic demands of the working myocardium.¹⁹

In the heart, Kv1.5 expression is largely confined to the atria where it is responsible for the ultrarapid outward current, IKur, the major repolarizing current that is active throughout phases 1–3 of the atrial action potential (AP).²⁰,²¹ Targeting of Kv1.5 activity/expression is currently regarded as a promising therapeutic approach to the treatment of atrial fibrillation (AF).²²–²⁵

Given the widespread importance of Kv1.5 in the cardiovascular system and elsewhere, it is perhaps unsurprising that it is regulated via numerous posttranslational modifications, including ubiquitination,²⁶ sumoylation,²⁶ palmitoylation,²⁷ phosphorylation²⁸,²⁹ and nitrosylation.³⁰ An additional means of regulation is via its sensitivity to reactive oxygen species (ROS). For example, tonic ROS production by mitochondria or NADPH oxidase (Nox 4) sustains Kv1.5 activity and keeps pulmonary VSMCs relatively hyperpolarized.³¹,³² In the coronary circulation, hydrogen peroxide (H₂O₂) has been proposed as the signal closely coupling cardiac metabolism to coronary blood flow³³–³⁵ and this coupling appears via H₂O₂-mediated augmentation of Kv1.5.³⁶ Recombinant Kv1.5 activity has also been demonstrated to be directly augmented by H₂O₂.³⁶

An additional modulator of Kv1.5 is nitric oxide (NO), a long-established, biologically active signalling molecule in the cardiovascular system as well as other tissues.³⁷–³⁹ NO regulates Kv1.5 via nitrosylation and activation of cGMP,³⁰ an effect which is of potential importance in the context of AF, given the important role of this channel in atrial electrical activity, and also the fact that NO bioavailability is reduced in AF and NO synthases (NOSs) can become uncoupled, leading to superoxide formation.³⁸,⁴⁰,⁴¹

Accumulating data continue to establish carbon monoxide (CO) as an important gasotransmitter alongside NO (and hydrogen sulphide), which acts to provide a range of beneficial

¹Division of Cardiovascular and Diabetes Research, LICAMM, Faculty of Medicine and Health, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK and§School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
²Corresponding author: C Peers, Division of Cardiovascular and Diabetes Research, Leeds Institute for Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK. Tel: +44 113 343 4714; Fax: +44 113 343 4803; E-mail: c.s.peers@leeds.ac.uk
³Current address: School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
⁴Current address: Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK.
Received 25.7.17; revised 19.9.17; accepted 21.9.17; Edited by A Finazzi-Agrò
Cardiovascular (and other) effects. All three of these gaso-
transmitters are products of distinct, widely distributed
enzymes.42,43 CO dilates coronary and other vessels44–46
and induction of heme oxygenase-1 (HO-1, which produces
CO) protects against, for example, myocardial infarction,
hypertension and vascular injury.47,48 CO accounts for
many of the effects of HO-1 induction49–51 and CO inhalation, as well
as CO-releasing molecules (CORMs), are being developed for
cardiovascular therapy.52,53 Importantly, HO-1 expression is
increased in AF and appears to provide protection against the
oxidative stress of this condition.54–56 Given the important role
for Kv1.5 in normal atrial function, its redox sensitivity and the
likely involvement of HO-1 as a means of providing protection
in AF, we have explored the potential for CO-mediated
regulation of Kv1.5 channels using both a recombinant
expression system and murine atrial (HL-1) cells.

Results

CO inhibits recombinant human Kv1.5. To examine any
potential modulation of Kv1.5 by CO, we applied the CORM,
CORM-2, to HEK293 cells stably expressing human Kv1.5
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2 caused a reversible inhibition of K+ current
amplitudes, and this was associated with a marked slowing
of activation kinetics (Figure 1c). By contrast, the inactive
amplitudes, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,
CO inhibits recombinant hKv1.5. (Figure 1). By contrast, the inactive
amplitude, and this was associated with a marked slowing
CORM-2 caused a reversible inhibition of K+ current
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2, to HEK293 cells stably expressing human Kv1.5
potential modulation of Kv1.5 by CO, we applied the CORM,

Figure 1  CO inhibits recombinant hKv1.5. (a) Time-series plot (generated by repeated step depolarizations from −80 to +50 mV in 100 ms duration, 0.2 Hz) obtained from a HEK293 cell stably expressing human Kv1.5 (hKv1.5). Plot shows normalized peak current amplitudes. For the period indicated by the horizontal bar, the cell was exposed to 30 μM CORM-2. (b) As in panel (a), except this cell was exposed to 30 μM iCORM (inactive breakdown product of CORM-2), as indicated. (c) Example currents from the plotted time series evoked before and during application of CORM-2 (upper) and iCORM (lower). (d) Left, currents evoked in a HEK293 cell expressing hKv1.5 before and during exposure to 30 μM CORM-2, as indicated. Currents were evoked by step-depolarizations from −60 to +80 mV. Right, Mean (± S.E.M., n=6) current-density versus voltage relationships obtained before (open symbols) and during (solid symbols) application of 30 μM CORM-2. (e) Concentration–response curve for CORM-2 inhibition of hKv1.5. Each point is the mean (± S.E.M., n=3–17 cells in each case) fractional inhibition caused by CORM-2. Data fit yields IC50 of 23 μM.
complex III of the electron transport chain (Figures 2c and d). Thus mitochondria appear to be the source of ROS involved in CO-mediated inhibition of hKv1.5.

CO is also known to activate NOS and soluble guanylyl cyclase (sGC) in several cell types. Pretreatment of cells (1 h at 37 °C) with the NOS inhibitor L-NAME (1 mM) significantly attenuated the ability of CORM-2 to inhibit hKv1.5 (Figures 2e and f). Similarly, pretreatment of cells (1 h at 37 °C) with the membrane-permeable sGC inhibitor, Rp-8-Br-cGMPS (100 nM), significantly reduced the inhibitory effects of CORM-2 on hKv1.5 (Figures 2e and f). Pretreatment of cells with both agents similarly reduced the ability of CO to inhibit currents (Figures 2e and f). These data suggested that CO could stimulate NO formation and this was further confirmed by monitoring NO levels in hKv1.5-expressing HEK293 cells using the NO-sensitive fluoroprobe, DAF-2 (Figures 3a and b). Application of CORM-2 (30 μM) to DAF-2-loaded cells caused a significant rise in fluorescence, which was fully attenuated following preincubation of cells with 1 mM L-NAME (1 h, 37 °C). It is likely, therefore, that CO inhibits hKv1.5 in part via activation of NO formation, as a previous study has suggested that NO can inhibit Kv1.5. NO inhibition was shown by Nunez et al. to be mediated partly via PKG-dependent phosphorylation, as is the case for CO (Figure 3), and also by nitrosylation. To explore nitrosylation as a mechanism for CO-mediated inhibition of hKv1.5, we employed the biotin-switch technique and detected nitrosylation of hKv1.5 protein by CORM-2 but not by iCORM (Figure 3c), indicating that CO does indeed stimulate nitrosylation of hKv1.5.

The observation that CO raises ROS levels (presumably levels of superoxide, as SOD mimetics ameliorated the effects of CO; Figure 2), and also raises NO levels suggests the possibility that peroxynitrite (ONOO−) formation occurs in the presence of CO, as we have previously suggested. In support of this idea, we found that CO increased the level of fluorescence in cells loaded with the ONOO− indicator, 2-[6-(4′-amino)phenoxyl]-3H-xanthen-3-on-9-ylbenzoic acid (APF; Figure 4a). These rises were fully attenuated by both L-NAME and the ONOO− scavenger, FeTPPS (Figures 4a and b). Furthermore, pretreatment of cells with FeTPPS strongly attenuated the CO-mediated inhibition of hKv1.5 (Figure 4c).

Exploring the roles of C346 and C331. Based on structural modelling, it has previously been suggested (but not demonstrated) that two cysteine (C) residues within hKv1.5 might be nitrosylated by NO and thereby account for its inhibitory action on the channel. As much of the effects of CO, as reported here, are mediated by NO formation (Figures 2 and 3), we explored the potential involvement of these two residues, C331 and C346. To do this, we generated C→A (alanine) substitution mutants. As shown in Figure 5, CO was still able to inhibit the activity of the C331A (Figure 5a) and C346A mutant channels (Figure 5b). The degree of inhibition caused by 30 μM CORM-2 (44 ± 8.6%, mean ± S.E.M., n = 5, P < 0.001 for C331A and 47 ± 1.7%,
mean ± S.E.M., n = 5, P < 0.001 for C346A) was not significantly different from the degree of inhibition seen in the WT (non-mutant) hKv1.5 channel. Furthermore, we could detect nitrosylation of both mutants using the biotin-switch technique (Figure 5c). These findings discount both C331 and C346 as important residues in the response of hKv1.5 to CO or NO.

CO reverses H$_2$O$_2$ augmentation of Kv1.5. The activity of both native and recombinant Kv1.5 channels has been shown to be augmented by H$_2$O$_2$. In agreement with these studies, we found that H$_2$O$_2$ (300 μM) augmented Kv1.5 activity. This effect was fully reversed by CORM-2 (30 μM), as exemplified in Figure 6a and quantified in Figure 6b. Given the partial prevention of the effects of CO by mitoTEMPO and SOD mimetics, this result suggests that H$_2$O$_2$ augmentation of Kv1.5 is an effect strikingly distinct from the formation of superoxide or ONOO$^-$ that contribute to CO inhibition of the channel.

Effects of CO in HL-1 atrial cells. To examine the potential for modulation of native Kv1.5 by CO, we employed the atrial cell line, HL-1. Using a voltage protocol designed to isolate IKur (which is attributable to Kv1.5 activity), step-depolarizations evoked outward K$^+$ currents that were strongly reduced in amplitude by the Kv1.5 inhibitor DPO-1 (1 μM; Figure 7a). These currents were also inhibited by CORM-2 (Figure 7b), suggesting that CO could inhibit native Kv1.5 channels in HL-1 cells, as it does recombinant Kv1.5 channels. Indeed, 30 μM CORM-2 caused a 49.8 ± 5% (n = 9) inhibition of currents at +50 mV, an effect quantitatively similar to that observed for recombinant channels (Figure 1). Furthermore, CORM-2 also evoked a measurable rise in NO levels in HL-1 cells, an effect that was effectively inhibited by L-NAME (Figure 7c), thereby suggesting an important role for NO in the actions of CO not only in HL-1 cells but also in HEK293 cells expressing hKv1.5.

Under current-clamp conditions, we also recorded spontaneous action potentials in HL-1 cells. We found that CORM-2 (30 μM) significantly increased action potential amplitudes and also increased their duration (Figures 8a and c). Importantly, a similar effect was seen when HL-1 cells were exposed to DPO-1 (Figures 8b and c). Furthermore, in the presence of DPO-1, CORM-2 did not increase the amplitude or duration of currents further (Figures 8b and c), suggesting that both CO and DPO-1 acted at the same site, Kv1.5. These findings suggest that CO inhibition of Kv1.5 may be physiologically significant for atrial excitability.

Discussion
The present study demonstrates that both native and recombinant hKv1.5 K$^+$ channels are inhibited by CO. This finding adds to the growing understanding of the complexity of CO signalling in cardiac and other tissues by describing a new ion channel target for regulation. Significantly, it also demonstrates, for the first time, a polymodal means of channel regulation by CO that is summarized in Figure 8d. Previously, we have shown that CO-mediated augmentation of the late cardiac Na$^+$ current is NO dependent and involves channel nitrosylation. Peak inward Na$^+$ current inhibition by CO is also NO dependent. Inhibition of the cardiac L-type Ca$^{2+}$ current by CO is dependent on mitochondrial ROS production but independent of NO formation. Most recently, we have shown that cardiac ERG (Kv11.1) channels are also inhibited by CO, specifically via the formation of ONOO$^-$.
study indicates that Kv1.5 is uniquely inhibited by CO acting via all of the aforementioned pathways as well as via cGMP formation, which presumably modifies channel activity via phosphorylation as suggested previously for the effects of NO.30

Each of these distinct means of Kv1.5 regulation by CO can be regarded as potentially important under varying physiological and pathological conditions, not only in the heart but also in the vasculature. Recent studies have provided evidence that H$_2$O$_2$ generated by cardiac myocytes couples cardiac metabolism to coronary flow by activating Kv1.5 channels in coronary VSMCs, which presumably leads to their relaxation (and hence vessel dilation) due to hyperpolarization and reduced Ca$^{2+}$ influx.30–33 CO raises ROS levels, yet reverses augmentation of Kv1.5 by H$_2$O$_2$ (Figure 6). This would suggest that ROS contributing to Kv1.5 inhibition by CO are likely to be either superoxide derived from mitochondria and/or ONOO$^-$ formed from superoxide and NO. It is clear that these ROS contribute to channel inhibition, whereas H$_2$O$_2$ has the opposite effect of augmenting current amplitudes – this suggests that Kv1.5 is differentially regulated by different oxidant species. Interestingly, CO-mediated inhibition of hKv1.5 was partly attenuated by the SOD mimetics MnTMPyP and MnTBAP (Figure 2). These agents would presumably increase H$_2$O$_2$ levels through superoxide dismutation, yet CO reversed the effects of exogenous H$_2$O$_2$ (Figure 6). This finding would suggest that CO-mediated inhibition of Kv1.5 via other mechanisms (e.g., nitrosylation or the sGC/cGMP pathway) can override augmentation by H$_2$O$_2$. This in turn suggests that CO levels may physiologically regulate H$_2$O$_2$-mediated coupling of coronary blood flow to cardiac metabolism.

Figures 2 and 3 indicate that NO formation has an important role in Kv1.5 inhibition by CO. Our findings in this regard are consistent with the study of Nunez et al.,30 who demonstrated that NO inhibited recombinant hKv1.5 via nitrosylation and a cGMP-dependent mechanism. The present study shows that CO also activates these pathways by stimulating a rise in NO levels. However, NO formation does not account for all of the effects of CO as detailed here. Although molecular modelling suggested C331 and C346 as candidate cysteine residues for nitrosylation,30 we found that both the C331A and C346A mutants remained sensitive to inhibition by CO (Figure 5). Furthermore, both mutant channels were nitrosylated by CO, suggesting that alternative cysteines in the Kv1.5 channel are preferentially targeted for nitrosylation. Physiologically, this

**Figure 4** CO stimulates ONOO$^-$ formation, which contributes to the inhibition of hKv1.5. (a) Example plots of the fluorescence levels in APF-loaded cells. At the point indicated by the arrow, cells were exposed to 30 μM CORM-2 alone (solid line) or following pretreatment for 1 h at 37 °C with FeTPPS (50 μM; dashed line) or L-NAME (1 mM; grey line). Also shown is the level of fluorescence detected in a cell exposed to 30 μM iCORM (dotted line). (b) Mean level of fluorescence detected in APF-loaded cells 5 min after exposure to CORM-2 alone or in the additional presence of FeTPPS or L-NAME or when exposed to iCORM or no drugs (control). Bars represent mean ± S.E.M. taken from between five and eight cells in each case. (c) Left, time-series plot (generated by repeated step-depolarizations from $-80$ to $+50$ mV (100 ms duration, 0.2 Hz)) obtained from a hKv1.5-expressing HEK293 cell previously exposed to 50 μM FeTPPS (1 h at 37 °C). Plot shows normalized peak current amplitudes. For the period indicated by the horizontal bar, the cell was exposed to 30 μM CORM-2. Inset shows example currents before and during CORM-2 exposure (scale bars: 1 nA (vertical), 50 ms (horizontal)). Right, bar graph showing the mean (± S.E.M.; n=5 cells) effects of CORM-2 following pretreatment with FeTPPS.
CO inhibition of Kv1.5 K⁺ channels
MM Al-Owais et al

Figure 5 Mutation of C331 or C346 does not impede CO-mediated inhibition of hKv1.5. (a) Time-series plot (generated by repeated step-depolarizations from −80 to +50 mV (100 ms duration, 0.2 Hz)) obtained from a HEK293 cell stably expressing hKv1.5 containing the C331A mutation. Plot shows normalized peak current amplitudes. For the period indicated by the horizontal bar, the cell was exposed to 30 μM CORM-2. Inset shows example currents recorded before and during CORM-2 application, as indicated. (b) As in panel (a), except currents were recorded from a cell stably expressing hKv1.5 containing the C346A mutation. (c) Nitrosylation of WT and mutant hKv1.5 channels was detected using the biotin-switch assay. Note: nitrosylation of hKv1.5 was only detected in samples treated with CORM-2, not iCORM.

Figure 6 CO reverses H₂O₂-mediated augmentation of hKv1.5 activity. (a) Left, time-series plot, generated by repeated step-depolarizations from −80 to +50 mV (100 ms duration, 0.2 Hz), obtained from a HEK293 cell stably expressing hKv1.5. Plot shows normalized peak current amplitudes. For the period indicated by the lower horizontal bar, 30 μM CORM-2 was also present. Right, example currents evoked before and during H₂O₂ application alone or together with CORM-2, as indicated. (b) Bar graph indicating the mean (± S.E.M. (n = 5)) percentage change in current amplitude caused by H₂O₂ alone or together with CORM-2, as indicated. *P < 0.05.

NO-dependent means by which CO regulates Kv1.5 activity is likely to be important both in the vasculature (particularly but not exclusively the coronary vasculature, as discussed above) and in the heart, where Kv1.5 exerts an important influence in shaping the atrial AP.²⁰,²¹ Kv1.5 is an important target for therapies aimed at treating AF;²³,⁵⁵ and interestingly, maintenance or augmentation of NO bioavailability is also considered a viable approach in the treatment of AF.⁴¹ Our data suggest that increasing CO levels (either via stimulating HO-1 expression or via CO donors⁵³) may therefore be of benefit in AF treatment via increased NO formation. However, elevated NO in the presence of superoxide can lead to the formation of ONOO⁻ and this was indeed observed in our study (Figure 4). ONOO⁻ formation is seen in AF⁶⁷,⁶⁸ and is presumably deleterious. Increased ONOO⁻ formation contributes to shortening of the effective refractory period seen in AF, but this is unlikely to arise from inhibition of Kv1.5, as this would be expected to prolong AP duration and therefore, presumably, the effective refractory period.

A noteworthy feature of the CO-mediated inhibition of Kv1.5 was the marked slowing of its activation kinetics (see Figure 1d), which was also prominent in the mutants (Figure 5). Slowing of activation by CO appears strikingly similar to the previously reported slowing of activation caused by zinc.⁶⁹ It would appear that this effect cannot be attributed to any particular single pathway of channel inhibition because residual inhibition caused by CO in the presence of SOD mimetics, NO or sGC inhibition or in the presence of FeTPPS to scavenge ONOO⁻ was not associated with a slowing of channel activation. This suggests that a combination of these signalling pathways is required in order to observe kinetic changes caused by CO together with channel inhibition.

To explore CO-mediated modulation of Kv1.5 in a more physiological setting, we investigated its ability to regulate K⁺ currents in the mouse atrial cell line, HL-1. Our data indicate that CO inhibits a DPO-1-sensitive K⁺ current in these cells and so presumably arises at least primarily due to activity of Kv1.5.⁶⁰ Our data do not exclude actions of CO on other cardiac ion channels, and indeed a number of such channels are known to be CO sensitive.⁶¹ However, inhibition of Kv1.5 does appear to be of functional significance, as it significantly...
increased AP amplitude and duration in a manner that was mimicked and occluded by DPO-1. Thus CO regulation of Kv1.5 is potentially of physiological significance for regulating atrial excitability. It may also be of pathological significance, for example, in atrial fibrillation, which is associated with increased expression of HO-1.

In summary, we have demonstrated that CO inhibits both native (mouse) and recombinant (human) Kv1.5 and does so via multiple signalling pathways. Tonic regulation of Kv1.5 by CO is likely to be of physiological relevance in cardiac atria as well as vascular smooth muscle, where it may regulate channel responses to other signalling factors (e.g., H2O2). The significance of Kv1.5 regulation by CO may increase under pathological conditions such as atrial fibrillation and vascular disease due to increased HO-1 expression.

Materials and Methods

Generation and culture of HEK293 cells expressing Kv1.5. Wild-type (WT) human Kv1.5 (KCNA5) cDNA was amplified from a human foetal brain cDNA library (Clontech, Wooburn Green, Buckinghamshire, UK) using the primers: 5′-TGGAATTCACCATGGAGATGCCTG-3′ and 5′-GACTCGAGTCACAAA TCTGTTTCCCG-3′ (Sigma-Aldrich, Gillingham, Dorset, UK) in a touchdown PCR. The ∼1.7 kb product was cloned using the CloneJET Kit (Thermo Fisher Scientific, Loughborough, Leicestershire, UK) and then subcloned into pcDNA6 (Invitrogen, Loughborough, Leicestershire, UK) using EcoRI and XhoI restriction enzymes (New England Biolabs, Hitchin, Hertfordshire, UK). At each step, clones were confirmed by Sanger sequencing (Genewiz, Bishop’s Stortford, Hertfordshire, UK).

HEK293 cells were cultured in MEM with Earle’s salts and L-glutamine, supplemented with 9% (v/v) fetal calf serum (Gibco-BRL, Esher, Surrey, UK), 1% (v/v) non-essential amino acids, 50 µg/ml gentamicin, 100 units/ml penicillin G, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin in a humidified atmosphere of air/CO2 (19 : 1) at 37 °C. All cell culture reagents were purchased from Gibco-BRL (Thermo Fisher Scientific) unless otherwise stated. HEK293 cells were cultured in MEM with Earle’s salts and L-glutamine, supplemented with 9% (v/v) fetal calf serum (Gibco-BRL, Esher, Surrey, UK), 1% (v/v) non-essential amino acids, 50 µg/ml gentamicin, 100 units/ml penicillin G, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin in a humidified atmosphere of air/CO2 (19 : 1) at 37 °C. All cell culture reagents were purchased from Gibco-BRL (Thermo Fisher Scientific) unless otherwise stated. To generate stable HEK293/Kv1.5 cell lines, cells were transfected with either a pcDNA6/Kv1.5(WT) or pcDNA6/Kv1.5(Mutant) construct using the PolyFect transfection reagent (Qiagen, Hybaid Ltd, Teddington, UK) according to the manufacturer’s instructions. Stable HEK293/Kv1.5 cell lines were achieved by antibiotic selection with blasticidin (5 µg/ml, Thermo Fisher Scientific), added to the medium 3 days after transfection. Selection was applied for 4 weeks (media changed every 4–5 days), after which time individual colonies were picked and seeded in T25 flasks and allowed to reach confluence. They were then
Cell Death and Disease

8

ROS (presumably superoxide, O2- mechanism for the inhibition of Kv1.5 by CO. Data presented suggest CO increases

There were no significant differences between the conditions. (**

Significant difference from control (no drug): ***

Figure 8  CO augments action potentials in HL-1 cells. (a) Spontaneous action

potentials (APs) recorded in an example HL-1 cell before (control) and during

application of 30 μM CORM-2. Note: CORM-2 increases the AP amplitude and

duration. (b) As in panel (a), except that the cell was exposed to DPO-1 (1 μM), then

CORM-2 (30 μM) in the continued presence of DPO-1. Note: DPO-1 augments APs

and prevents further augmentation by CORM-2. (c) Mean (± S.E.M.) augmentation in AP

amplitude (AP amp.; left) and APD50 (right) caused by CORM-2 alone (n = 10),

DPO-1 (n = 9) alone or CORM-2 in the continued presence of DPO-1 (both; n = 8).

Significant difference from control (no drug): ***P < 0.001, **P < 0.01, *P < 0.05.

There were no significant differences between the conditions. (d) Schematic

mechanism for the inhibition of Kv1.5 by CO. Data presented suggest CO increases ROS

[presumably superoxide, O2-] formation from mitochondria, which may
directly regulate Kv1.5, but can also combine with NO (levels of which increase in

response to CO) to form peroxynitrite (ONOO-), to cause channel inhibition.

Elevated NO levels also directly nitrosylate Kv1.5. CO can also stimulate sGC (an

effect that is also promoted by elevated NO levels), which leads to channel

phosphorylation

transferred to T75 flasks for further culture and examination of K+ currents. Cells were

harvested from culture flasks by trypsinization and plated onto coverslips 24–48 h

before use in electrophysiological studies. Blastocidin selection was maintained

throughout the entire cloning process at 5 μg/ml and then subsequently reduced to

2.5 μg/ml in all subsequent passages of cells once stable clones had been positively

identified.

The C331A and C346A mutations were introduced into WT human Kv1.5 (hKv1.5,
in pcDNA6) using the Quik-Change Site-Directed Mutagenesis Kit (Stratagene,

Cheddle, UK) according to the manufacturer’s instructions. All constructs were

verified by DNA sequence analysis before transfection.

Culture of HL-1 cells. HL-1 atrial cardiomyocytes were maintained in

Claycomb media (Sigma, UK) supplemented with batch-specific 10% FBS (Sigma,

Gillingham), 1% penicillin/streptomycin (Invitrogen), 0.1 mM norepinephrine (Sigma)

and 2 mM l-glutamine (Invitrogen). Cells were cultured in flasks, or on coverslips,
treated with 0.02% Bacto gelatin (Fisher Scientific, Loughborough, UK) and 0.5% fibronectin (Invitrogen).

Exposure to CO. CO was applied to HEK293 cells and HL-1 cells via the

CORM, CORM-2. CORM-2 was prepared no longer than 1 h before use by

dissolving in dimethylsulphoxide (DMSO) at a stock concentration of 30 mM so that

dilution into perfusate or other solutions in which cells were maintained (e.g.,
electrophysiology, imaging, biotin switch assay) usually resulted in DMSO levels of

no more than 1: 1000. iCORM, which served as a negative control, was prepared

dissolving in CO-diluted 0.02% DMSO, which was applied to HL-1 cells

immediately prior to use, by which time all CO was released and lost from solution.

Electrophysiology. Coverslips with cultured cells were transferred from the

incubator into a recording chamber mounted on the stage of an Olympus CK40

inverted microscope (Olympus, London, UK) and continually perfused with bath

solution (2–4 ml.min-1) containing the following: 140 mM NaCl, 4 mM KCl, 2 mM

CaCl2, 1 mM MgCl2, 5 mM glucose, buffered with 10 mM HEPES, pH 7.4. Single

cells were selected for whole-cell patch-clamp experiments at 22 ± 1 °C. Pipettes

were filled with intracellular solution (140 mM KCl, 10 mM NaCl, 4 mM MgCl2,

20 mM EGTA, 10 mM HEPES, pH 7.2) and had a resistance of 4–6 MΩ. Whole-cell

voltage-clamp or current-clamp experiments were recorded, digitized and stored

with an Axopatch 200B amplifier, Digitida 1322A and pCLAMP 10 respectively

(Molecular Devices, Union City, CA, USA).

Series resistance was compensated by 70–90%. If a significant increase in series

resistance occurred (> 20%), the experiment was terminated. Leak currents were

subtracted using the P/4 protocol in the pCLAMP software and voltage-clamp signals

were sampled at 50 kHz and low-pass filtered at 20 kHz. I-V relationships were

measured by stepping from a holding potential of −90 mV to voltages between −60

and +80 mV in 10 mV increments for 500 ms. Time-series experiments were

measured using a single pulse protocol stepping from −90 to +50 mV for 100 ms

every 5 s.

HL-1 spontaneous APs were acquired in gap-free mode with no current injected. IKur

was recorded as described previously70 using a 100 ms prepulse to +40 mV to

inactivate IKur, followed by a 150 ms test pulse from −50 to between −40 and +50,
them to −30 mV.

Offline analysis was performed using the data analysis package Clampfit 10.0

(Molecular Devices, Foster City, CA, USA), and subsequent fitting and statistical

analysis was undertaken using GraphPad Prism 7 (GraphPad Software, La Jolla, CA,

USA). Results are presented as means ± S.E.M., with ‘n’ representing the number of

experiments performed. Statistical significance was evaluated using unpaired

Student’s t tests where differences were considered significant when the

p-value was <0.05.

Biotin-switch assay. Detection of S-nitrosylated hKv1.5 was performed using the

biotin-switch assay followed by western blotting as previously described.71

Briefly, HEK293 cells expressing WT or mutant (C331A or C346A) Kv1.5

were harvested and lysed in a non-denaturing solution (in mM: 50 Tris-HCl, 300 NaCl,

5 EDTA, 1% Triton-X). Extracts were adjusted to 0.5 mg/ml and incubated with

CORM-2 (30 μM) for 15 min at 37 °C; inactive CORM (iCORM, 30 μM) and DMSO

were used as controls.

CORM-2 and iCORM were removed and buffered exchanged using desalting spin

columns (Thermo Fisher Scientific). From this point, all procedures were carried out in

do dark. Lysates were incubated in blocking buffer (in mM: 225 HEPES, 0.9 EDTA, 20

methyl methanethiosulfonate (MMTS), and 2.5% SDS, pH 7.4) for 20 min at 50 °C

with agitation. Lysates were subjected to buffer exchange to remove MMTS and

eluted in HENS buffer (in mM: 250 HEPES, 1 EDTA, and 1% SDS, pH 7.4) and

incubated with 1/3 volume of N-[6-(biotinamido)hexyl]-3′-[2′-pyridyldithio) propiona-

amide (biotin-HPDP, Pierce, Loughborough, UK) and aspirate (1 mM) for 1 h at room

temperature, followed by buffer exchange to remove biotin-HPDP from the samples.

Unless otherwise stated, all buffers were supplemented with protease inhibitor

tablets (Roche, Welwyn Garden City, UK).
Biotinylated proteins were detected via western blotting as described previously.28 Protein samples were prepared without reducing agents and were not boiled before electrophoresis to prevent the reversal of cysteine biotinylation and non-specific biotin–HPDP reactions, respectively.

**Fluorescence detection of nitric oxide (NO) and peroxynitrite (ONOO−).** Cells were plated on coverslips and allowed to grow for 48 h at 37 °C in a humidified atmosphere containing 95% air and 5% CO2 before being preincubated for 1 h with DAF-2 diacetate (5 μM; Invitrogen), prepared in the following extracellular solution: 140 mM NaCl, 4 mM KCl, 1.5 mM CaCl2,2 mM MgCl2, 10 mM HEPES, 10 mM glucose, pH 7.4). Cells were then gently washed twice with extracellular solution and then left for at least 15 min in an incubator to allow the hydrolysis of DAF-2 diacetate into the free NO-sensitive free acid form (DAF-2).

**Conflict of Interest**
The authors declare no conflict of interest.

**Acknowledgements.** This work was supported by the British Heart Foundation.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


